Nonalcoholic Fatty Liver Disease in Children: Where Are We?

Epidemiology of non-alcoholic fatty liver disease in China

Common Genetic Variants and Nonalcoholic Fatty Liver Disease

Prevalence of Elevated Alanine Aminotransferase Among US Adolescents and Associated Factors: NHANES 1999–2004

Lean Fatty Liver Disease: Through Thick and Thin

Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons

Biomarkers in Fatty Liver Disease—Here is the Skinny

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and, indeed, worldwide. It has become a global public health issue. In the United States, the prevalence in the general population is estimated at approximately 20%, while that in the morbidly obese population at approximately 75-92% and in the pediatric population at approximately 13-14%. The progressive form of NAFLD, nonalcoholic steatohepatitis, is estimated at approximately 3-5%, with approximately 3-5% of these having progressed to cirrhosis. Thus, the numbers of individuals at risk for end-stage liver disease and development of primary liver cancer is large. NAFLD is an independent risk factor for cardiovascular disease, leads to increased all-cause mortality, and to increased liver-related mortality. This review focuses on recent advances in our understanding of the NAFLD disease spectrum, including etiology, diagnosis, treatment, and genetic and environmental risk factors and suggests future directions for research in this important area.

Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins

Abnormal aminotransferase activity in women with polycystic ovary syndrome

Referral pathways for NAFLD fibrosis in primary care – No longer a ‘needle in a haystack’

Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease

Combined alcoholic and non-alcoholic steatohepatitis.

Evaluation and management of non-alcoholic steatohepatitis

Liquid biomarkers for fibrotic NASH – progress in a complex field